Stock Track | Relay Therapeutics Plunges Nearly 6% After Q3 Earnings Miss and Higher Net Loss

Stock Track11-07

Relay Therapeutics (NASDAQ: RLAY) saw its stock price plummet by 5.97% in Friday's trading session following the release of its third-quarter financial results. The clinical-stage precision medicine company reported a larger-than-expected loss, disappointing investors and analysts alike.

For the quarter ended September 30, Relay Therapeutics posted a net loss of $74.1 million, or $0.43 per share, slightly missing the analyst consensus estimate of a $0.42 per share loss. This represents a marginal improvement from the $0.63 per share loss reported in the same period last year. The company's operating expenses for the quarter totaled $80.391 million, with research and development expenses accounting for $68.3 million of that amount.

Despite the wider-than-expected loss, Relay Therapeutics highlighted some positive developments. The company ended the quarter with a strong cash position of approximately $596 million in cash, cash equivalents, and investments. Management expressed confidence that this financial cushion would be sufficient to fund operations into 2029, providing a long runway for its clinical programs. Additionally, Relay Therapeutics continued to advance its clinical trials for RLY-2608 in breast cancer and vascular malformations, and announced the appointment of two new board members, Lonnel Coats and Habib J. Dable, potentially bringing fresh perspectives to the company's leadership.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1173516124?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 14:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173516124","market":"us","top_or_hot":-1,"title":"Stock Track | Relay Therapeutics Plunges Nearly 6% After Q3 Earnings Miss and Higher Net Loss","media":"Stock Track","content":"<p>Relay Therapeutics (NASDAQ: RLAY) saw its stock price plummet by 5.97% in Friday's trading session following the release of its third-quarter financial results. The clinical-stage precision medicine company reported a larger-than-expected loss, disappointing investors and analysts alike.</p>\n\n<p>For the quarter ended September 30, Relay Therapeutics posted a net loss of $74.1 million, or $0.43 per share, slightly missing the analyst consensus estimate of a $0.42 per share loss. This represents a marginal improvement from the $0.63 per share loss reported in the same period last year. The company's operating expenses for the quarter totaled $80.391 million, with research and development expenses accounting for $68.3 million of that amount.</p>\n\n<p>Despite the wider-than-expected loss, Relay Therapeutics highlighted some positive developments. The company ended the quarter with a strong cash position of approximately $596 million in cash, cash equivalents, and investments. Management expressed confidence that this financial cushion would be sufficient to fund operations into 2029, providing a long runway for its clinical programs. Additionally, Relay Therapeutics continued to advance its clinical trials for RLY-2608 in breast cancer and vascular malformations, and announced the appointment of two new board members, Lonnel Coats and Habib J. Dable, potentially bringing fresh perspectives to the company's leadership.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Relay Therapeutics Plunges Nearly 6% After Q3 Earnings Miss and Higher Net Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Relay Therapeutics Plunges Nearly 6% After Q3 Earnings Miss and Higher Net Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-07 14:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Relay Therapeutics (NASDAQ: RLAY) saw its stock price plummet by 5.97% in Friday's trading session following the release of its third-quarter financial results. The clinical-stage precision medicine company reported a larger-than-expected loss, disappointing investors and analysts alike.</p>\n\n<p>For the quarter ended September 30, Relay Therapeutics posted a net loss of $74.1 million, or $0.43 per share, slightly missing the analyst consensus estimate of a $0.42 per share loss. This represents a marginal improvement from the $0.63 per share loss reported in the same period last year. The company's operating expenses for the quarter totaled $80.391 million, with research and development expenses accounting for $68.3 million of that amount.</p>\n\n<p>Despite the wider-than-expected loss, Relay Therapeutics highlighted some positive developments. The company ended the quarter with a strong cash position of approximately $596 million in cash, cash equivalents, and investments. Management expressed confidence that this financial cushion would be sufficient to fund operations into 2029, providing a long runway for its clinical programs. Additionally, Relay Therapeutics continued to advance its clinical trials for RLY-2608 in breast cancer and vascular malformations, and announced the appointment of two new board members, Lonnel Coats and Habib J. Dable, potentially bringing fresh perspectives to the company's leadership.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RLAY","symbol_name":"Relay Therapeutics","start_time":0,"source_url":"","article_id":"1173516124","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173516124","pubTimestamp":1762496557,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Relay Therapeutics (NASDAQ: RLAY) saw its stock price plummet by 5.97% in Friday's trading session following the release of its third-quarter financial results. The clinical-stage precision medicine...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RLAY":"Relay Therapeutics"},"translate_title":"个股追踪|Relay Therapeutics在第三季度盈利未达预期且净亏损增加后暴跌近6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLAY":1},"content_text":"Relay Therapeutics (NASDAQ: RLAY) saw its stock price plummet by 5.97% in Friday's trading session following the release of its third-quarter financial results. The clinical-stage precision medicine company reported a larger-than-expected loss, disappointing investors and analysts alike.\nFor the quarter ended September 30, Relay Therapeutics posted a net loss of $74.1 million, or $0.43 per share, slightly missing the analyst consensus estimate of a $0.42 per share loss. This represents a marginal improvement from the $0.63 per share loss reported in the same period last year. The company's operating expenses for the quarter totaled $80.391 million, with research and development expenses accounting for $68.3 million of that amount.\nDespite the wider-than-expected loss, Relay Therapeutics highlighted some positive developments. The company ended the quarter with a strong cash position of approximately $596 million in cash, cash equivalents, and investments. Management expressed confidence that this financial cushion would be sufficient to fund operations into 2029, providing a long runway for its clinical programs. Additionally, Relay Therapeutics continued to advance its clinical trials for RLY-2608 in breast cancer and vascular malformations, and announced the appointment of two new board members, Lonnel Coats and Habib J. Dable, potentially bringing fresh perspectives to the company's leadership.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173516124","isCrawlerRequest":true}